Skye Bioscience SEC Filings

Skye Bioscience Chief Medical Officer granted stock options. On February 6, 2026, Chief Medical Officer Puneet S. Arora received a stock option to buy 125,000 shares of Skye Bioscience common stock at an exercise price of $0.82 per share. The option vests in equal monthly installments over four years beginning January 19, 2026, and is held directly by the reporting person.

Skye Bioscience Chief Executive Officer and director Punit Dhillon reported a grant of stock options. On February 6, 2026, he was awarded an option to buy 280,000 shares of common stock at an exercise price of $0.82 per share, held directly.

The option vests in equal monthly installments over a four-year period beginning January 19, 2026 and expires on February 6, 2036. Following this grant, Dhillon beneficially owns 280,000 derivative securities in the form of this stock option.

Skye Bioscience reported interim results from the combination cohort of its Phase 2a extension study of nimacimab for obesity. Nineteen participants who completed 26 weeks entered a further 26-week blinded extension, remaining on either nimacimab plus semaglutide or placebo plus semaglutide.

In the nimacimab plus semaglutide arm, mean weight loss was 14.4% at 26 weeks; seven completers lost an additional 7.9% over the extension, for 22.3% mean loss at 52 weeks. In the placebo plus semaglutide arm, mean weight loss was 13.9% at 26 weeks; seven completers lost an additional 5.8%, for 19.7% mean loss at 52 weeks. The combination remained safe and well tolerated, with no serious adverse events or adverse events of special interest reported.

The company expects full topline Phase 2a extension data, including nimacimab monotherapy and a 13-week off-therapy follow-up, in Q3 2026. It currently expects its capital to fund operations and key clinical milestones into the fourth quarter of 2026, excluding anticipated clinical and manufacturing costs for a proposed higher-dose Phase 2b trial.

Skye Bioscience furnished an update on its business and reported financial results for the period ended September 30, 2025 via a press release attached to a Form 8-K.

The company submitted the press release as Exhibit 99.1 under Item 2.02. Consistent with General Instruction B.2, this information is furnished and not deemed filed under the Exchange Act.

Skye Bioscience (SKYE) filed its Q3 2025 10‑Q, reporting wider losses as it advances obesity drug development. The company posted a net loss of $12,754,660 for the quarter. Operating expenses rose to $13,264,534, driven by research and development of $9,357,444 and general and administrative costs of $3,907,090.

Liquidity remained solid for near‑term plans: cash and cash equivalents were $18,441,079 and short‑term investments were $16,871,229, totaling $35,312,308 as of September 30, 2025. Total stockholders’ equity was $32,836,185. As of November 7, 2025, 32,057,461 shares were outstanding.

In its CBeyond Phase 2a study, nimacimab monotherapy did not meet the primary endpoint for weight loss versus placebo. However, the combination of nimacimab 200 mg with semaglutide showed greater weight loss than semaglutide alone at 26 weeks and maintained a favorable safety profile. The 26‑week extension enrolled 43 patients, with data expected in Q1 2026.

Skye Bioscience, Inc. (SKYE) announced it will host a conference call and live webcast to discuss a material event on October 6, 2025 at 8:00 a.m. ET. The filing states that the information under Item 7.01, including Exhibit 99.1, is being furnished and expressly notes it is not being "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other SEC filings except by specific reference. No financial results, tables, transactions, or additional details are included in the disclosed text.

Insider sales by a director/10% owner over two days. Andrew J. Schwab, reporting as a director and a 10% owner through affiliated 5AM entities, reported multiple open-market dispositions of Skye Bioscience (SKYE) common stock on 08/21/2025 and 08/22/2025. The filings show weighted-average sale prices in two ranges: $3.55–$3.69 for 08/21 and $3.30–$3.59 for 08/22. Reported individual dispositions total 58,642; 2,314; 163,979; and 6,470 shares across the two days, with ownership reported on various lines as indirect through 5AM Ventures II, 5AM Co-Investors II, and 5AM Ventures VII. The form is signed by Mr. Schwab on 08/22/2025.

Skye Bioscience insiders reported multiple sales of common stock on August 21-22, 2025. Entities affiliated with 5AM sold a total of 231,405 shares across two days at weighted-average prices of $3.57 (sales on 08/21) and $3.42 (sales on 08/22), with transaction prices in footnotes ranging from $3.30 to $3.69. After the reported transactions, the filing shows beneficial ownership positions including 1,621,043, 63,963, 1,457,064, 57,493 and a block of 8,167,206 shares held indirectly by 5AM-affiliated entities. The report is signed by the applicable 5AM entities and individual managing members.

Schonfeld Strategic Advisors LLC filed an amendment to a Schedule 13G reporting ownership of 1,115,939 shares of Skye Bioscience, Inc. common stock, representing 3.60% of the class. The filing states those shares are held for the ordinary course of business and not for the purpose of influencing control. Schonfeld reports sole voting and dispositive power over the reported shares and notes that some shares are held in separately managed accounts for clients who retain the right to dividends or sale proceeds.